Myeloid-derived suppressor cells in cancer: Current knowledge and future perspectives.

Area of Science:

• Immunology
• Oncology
• Cancer Research

Background:

• Myeloid-derived suppressor cells (MDSCs) are key players in cancer immune evasion.
• MDSCs accumulate in tumors and blood, suppressing anti-cancer immune cells like T-cells and NK cells.
• They promote tumor growth, angiogenesis, and metastasis, creating a pro-tumorigenic environment.

Purpose of the Study:

• To provide a comprehensive review of myeloid-derived suppressor cells (MDSCs) in cancer.
• To detail the regulation of MDSC development and function.
• To discuss MDSCs as prognostic/predictive biomarkers and explore therapeutic targeting strategies.

Main Methods:

• Literature review of existing research on MDSCs in cancer.
• Analysis of MDSC roles in immune suppression, angiogenesis, and metastasis.
• Examination of current and emerging therapeutic approaches targeting MDSCs.

Main Results:

• MDSC accumulation correlates with poor prognosis and therapeutic resistance in cancer patients.
• MDSCs actively suppress various immune cells, contributing to immune evasion.
• Targeting MDSCs holds potential for enhancing cancer therapy efficacy and immune surveillance.

Conclusions:

• MDSCs are critical mediators of tumor immune escape and represent a significant therapeutic target.
• Understanding MDSC regulation and function is vital for developing effective cancer treatments.
• Targeting MDSCs may improve patient outcomes by overcoming immune suppression and enhancing anti-tumor immunity.